Global Biopharmaceuticals Market to Reach $1.2 Trillion by 2030

New York, March 15, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Biopharmaceuticals Industry" - https://www.reportlinker.com/p06051422/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Biopharmaceuticals Market to Reach $1.2 Trillion by 2030

In the changed post COVID-19 business landscape, the global market for Biopharmaceuticals estimated at US$466.3 Billion in the year 2022, is projected to reach a revised size of US$1.2 Trillion by 2030, growing at aCAGR of 12.2% over the period 2022-2030. Monoclonal Antibody, one of the segments analyzed in the report, is projected to record 9% CAGR and reach US$692.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Erythropoietin segment is readjusted to a revised 12.9% CAGR for the next 8-year period.

The U.S. Market is Estimated at $127 Billion, While China is Forecast to Grow at 17.1% CAGR

The Biopharmaceuticals market in the U.S. is estimated at US$127 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$276.4 Billion by the year 2030 trailing a CAGR of 17.1% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.1% and 7.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.7% CAGR.

Select Competitors (Total 214 Featured)
- Abbott Diagnostics, Inc. - Core Laboratory
- Amgen, Inc.
- Biogen, Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Johnson & Johnson
- Merck & Co., Inc.
- Novo Nordisk A/S
- Pfizer, Inc.
- Sanofi


Read the full report: https://www.reportlinker.com/p06051422/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Biopharmaceuticals - Global Key Competitors Percentage Market
Share in 2021 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2021 (E)
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Biopharmaceuticals
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 2: World Historic Review for Biopharmaceuticals by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Biopharmaceuticals by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Monoclonal
Antibody by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Monoclonal Antibody by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Monoclonal Antibody by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Interferon by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for Interferon by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Interferon by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Insulin by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for Insulin by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Insulin by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Growth &
Coagulation Factor by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Growth & Coagulation Factor
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Growth & Coagulation
Factor by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 16: World Current & Future Analysis for Erythropoietin by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 17: World Historic Review for Erythropoietin by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Erythropoietin by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Vaccine by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 20: World Historic Review for Vaccine by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 21: World 15-Year Perspective for Vaccine by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Hormone by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Hormone by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 24: World 15-Year Perspective for Hormone by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Other Products by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 26: World Historic Review for Other Products by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Other Products by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Oncology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 29: World Historic Review for Oncology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 30: World 15-Year Perspective for Oncology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Blood Disorder by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 32: World Historic Review for Blood Disorder by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Blood Disorder by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 34: World Current & Future Analysis for Metabolic Disease
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 35: World Historic Review for Metabolic Disease by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 36: World 15-Year Perspective for Metabolic Disease by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 37: World Current & Future Analysis for Infectious
Disease by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 38: World Historic Review for Infectious Disease by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 39: World 15-Year Perspective for Infectious Disease by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 40: World Current & Future Analysis for Cardiovascular
Disease by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 41: World Historic Review for Cardiovascular Disease by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 42: World 15-Year Perspective for Cardiovascular Disease
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 43: World Current & Future Analysis for Neurological
Disease by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 44: World Historic Review for Neurological Disease by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 45: World 15-Year Perspective for Neurological Disease by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 46: World Current & Future Analysis for Immunology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 47: World Historic Review for Immunology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 48: World 15-Year Perspective for Immunology by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 49: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 50: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 51: World 15-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Biopharmaceuticals Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United States for 2023 (E)
Table 52: USA Current & Future Analysis for Biopharmaceuticals
by Product - Monoclonal Antibody, Interferon, Insulin, Growth &
Coagulation Factor, Erythropoietin, Vaccine, Hormone and Other
Products - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 53: USA Historic Review for Biopharmaceuticals by Product -
Monoclonal Antibody, Interferon, Insulin, Growth &
Coagulation Factor, Erythropoietin, Vaccine, Hormone and Other
Products Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 54: USA 15-Year Perspective for Biopharmaceuticals by
Product - Percentage Breakdown of Value Sales for Monoclonal
Antibody, Interferon, Insulin, Growth & Coagulation Factor,
Erythropoietin, Vaccine, Hormone and Other Products for the
Years 2012, 2020 & 2027

Table 55: USA Current & Future Analysis for Biopharmaceuticals
by Application - Oncology, Blood Disorder, Metabolic Disease,
Infectious Disease, Cardiovascular Disease, Neurological
Disease, Immunology and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 56: USA Historic Review for Biopharmaceuticals by
Application - Oncology, Blood Disorder, Metabolic Disease,
Infectious Disease, Cardiovascular Disease, Neurological
Disease, Immunology and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 57: USA 15-Year Perspective for Biopharmaceuticals by
Application - Percentage Breakdown of Value Sales for Oncology,
Blood Disorder, Metabolic Disease, Infectious Disease,
Cardiovascular Disease, Neurological Disease, Immunology and
Other Applications for the Years 2012, 2020 & 2027

CANADA
Table 58: Canada Current & Future Analysis for
Biopharmaceuticals by Product - Monoclonal Antibody,
Interferon, Insulin, Growth & Coagulation Factor,
Erythropoietin, Vaccine, Hormone and Other Products -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 59: Canada Historic Review for Biopharmaceuticals by
Product - Monoclonal Antibody, Interferon, Insulin, Growth &
Coagulation Factor, Erythropoietin, Vaccine, Hormone and Other
Products Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 60: Canada 15-Year Perspective for Biopharmaceuticals by
Product - Percentage Breakdown of Value Sales for Monoclonal
Antibody, Interferon, Insulin, Growth & Coagulation Factor,
Erythropoietin, Vaccine, Hormone and Other Products for the
Years 2012, 2020 & 2027

Table 61: Canada Current & Future Analysis for
Biopharmaceuticals by Application - Oncology, Blood Disorder,
Metabolic Disease, Infectious Disease, Cardiovascular Disease,
Neurological Disease, Immunology and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 62: Canada Historic Review for Biopharmaceuticals by
Application - Oncology, Blood Disorder, Metabolic Disease,
Infectious Disease, Cardiovascular Disease, Neurological
Disease, Immunology and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 63: Canada 15-Year Perspective for Biopharmaceuticals by
Application - Percentage Breakdown of Value Sales for Oncology,
Blood Disorder, Metabolic Disease, Infectious Disease,
Cardiovascular Disease, Neurological Disease, Immunology and
Other Applications for the Years 2012, 2020 & 2027

JAPAN
Biopharmaceuticals Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Japan for 2023 (E)
Table 64: Japan Current & Future Analysis for
Biopharmaceuticals by Product - Monoclonal Antibody,
Interferon, Insulin, Growth & Coagulation Factor,
Erythropoietin, Vaccine, Hormone and Other Products -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 65: Japan Historic Review for Biopharmaceuticals by
Product - Monoclonal Antibody, Interferon, Insulin, Growth &
Coagulation Factor, Erythropoietin, Vaccine, Hormone and Other
Products Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 66: Japan 15-Year Perspective for Biopharmaceuticals by
Product - Percentage Breakdown of Value Sales for Monoclonal
Antibody, Interferon, Insulin, Growth & Coagulation Factor,
Erythropoietin, Vaccine, Hormone and Other Products for the
Years 2012, 2020 & 2027

Table 67: Japan Current & Future Analysis for
Biopharmaceuticals by Application - Oncology, Blood Disorder,
Metabolic Disease, Infectious Disease, Cardiovascular Disease,
Neurological Disease, Immunology and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 68: Japan Historic Review for Biopharmaceuticals by
Application - Oncology, Blood Disorder, Metabolic Disease,
Infectious Disease, Cardiovascular Disease, Neurological
Disease, Immunology and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 69: Japan 15-Year Perspective for Biopharmaceuticals by
Application - Percentage Breakdown of Value Sales for Oncology,
Blood Disorder, Metabolic Disease, Infectious Disease,
Cardiovascular Disease, Neurological Disease, Immunology and
Other Applications for the Years 2012, 2020 & 2027

CHINA
Biopharmaceuticals Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in China for 2023 (E)
Table 70: China Current & Future Analysis for
Biopharmaceuticals by Product - Monoclonal Antibody,
Interferon, Insulin, Growth & Coagulation Factor,
Erythropoietin, Vaccine, Hormone and Other Products -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 71: China Historic Review for Biopharmaceuticals by
Product - Monoclonal Antibody, Interferon, Insulin, Growth &
Coagulation Factor, Erythropoietin, Vaccine, Hormone and Other
Products Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 72: China 15-Year Perspective for Biopharmaceuticals by
Product - Percentage Breakdown of Value Sales for Monoclonal
Antibody, Interferon, Insulin, Growth & Coagulation Factor,
Erythropoietin, Vaccine, Hormone and Other Products for the
Years 2012, 2020 & 2027

Table 73: China Current & Future Analysis for
Biopharmaceuticals by Application - Oncology, Blood Disorder,
Metabolic Disease, Infectious Disease, Cardiovascular Disease,
Neurological Disease, Immunology and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 74: China Historic Review for Biopharmaceuticals by
Application - Oncology, Blood Disorder, Metabolic Disease,
Infectious Disease, Cardiovascular Disease, Neurological
Disease, Immunology and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 75: China 15-Year Perspective for Biopharmaceuticals by
Application - Percentage Breakdown of Value Sales for Oncology,
Blood Disorder, Metabolic Disease, Infectious Disease,
Cardiovascular Disease, Neurological Disease, Immunology and
Other Applications for the Years 2012, 2020 & 2027

EUROPE
Biopharmaceuticals Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Europe for 2023 (E)
Table 76: Europe Current & Future Analysis for
Biopharmaceuticals by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 77: Europe Historic Review for Biopharmaceuticals by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 78: Europe 15-Year Perspective for Biopharmaceuticals by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2020 & 2027

Table 79: Europe Current & Future Analysis for
Biopharmaceuticals by Product - Monoclonal Antibody,
Interferon, Insulin, Growth & Coagulation Factor,
Erythropoietin, Vaccine, Hormone and Other Products -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 80: Europe Historic Review for Biopharmaceuticals by
Product - Monoclonal Antibody, Interferon, Insulin, Growth &
Coagulation Factor, Erythropoietin, Vaccine, Hormone and Other
Products Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 81: Europe 15-Year Perspective for Biopharmaceuticals by
Product - Percentage Breakdown of Value Sales for Monoclonal
Antibody, Interferon, Insulin, Growth & Coagulation Factor,
Erythropoietin, Vaccine, Hormone and Other Products for the
Years 2012, 2020 & 2027

Table 82: Europe Current & Future Analysis for
Biopharmaceuticals by Application - Oncology, Blood Disorder,
Metabolic Disease, Infectious Disease, Cardiovascular Disease,
Neurological Disease, Immunology and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 83: Europe Historic Review for Biopharmaceuticals by
Application - Oncology, Blood Disorder, Metabolic Disease,
Infectious Disease, Cardiovascular Disease, Neurological
Disease, Immunology and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 84: Europe 15-Year Perspective for Biopharmaceuticals by
Application - Percentage Breakdown of Value Sales for Oncology,
Blood Disorder, Metabolic Disease, Infectious Disease,
Cardiovascular Disease, Neurological Disease, Immunology and
Other Applications for the Years 2012, 2020 & 2027

FRANCE
Biopharmaceuticals Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in France for 2023 (E)
Table 85: France Current & Future Analysis for
Biopharmaceuticals by Product - Monoclonal Antibody,
Interferon, Insulin, Growth & Coagulation Factor,
Erythropoietin, Vaccine, Hormone and Other Products -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 86: France Historic Review for Biopharmaceuticals by
Product - Monoclonal Antibody, Interferon, Insulin, Growth &
Coagulation Factor, Erythropoietin, Vaccine, Hormone and Other
Products Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 87: France 15-Year Perspective for Biopharmaceuticals by
Product - Percentage Breakdown of Value Sales for Monoclonal
Antibody, Interferon, Insulin, Growth & Coagulation Factor,
Erythropoietin, Vaccine, Hormone and Other Products for the
Years 2012, 2020 & 2027

Table 88: France Current & Future Analysis for
Biopharmaceuticals by Application - Oncology, Blood Disorder,
Metabolic Disease, Infectious Disease, Cardiovascular Disease,
Neurological Disease, Immunology and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 89: France Historic Review for Biopharmaceuticals by
Application - Oncology, Blood Disorder, Metabolic Disease,
Infectious Disease, Cardiovascular Disease, Neurological
Disease, Immunology and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 90: France 15-Year Perspective for Biopharmaceuticals by
Application - Percentage Breakdown of Value Sales for Oncology,
Blood Disorder, Metabolic Disease, Infectious Disease,
Cardiovascular Disease, Neurological Disease, Immunology and
Other Applications for the Years 2012, 2020 & 2027

GERMANY
Biopharmaceuticals Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Germany for 2023 (E)
Table 91: Germany Current & Future Analysis for
Biopharmaceuticals by Product - Monoclonal Antibody,
Interferon, Insulin, Growth & Coagulation Factor,
Erythropoietin, Vaccine, Hormone and Other Products -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 92: Germany Historic Review for Biopharmaceuticals by
Product - Monoclonal Antibody, Interferon, Insulin, Growth &
Coagulation Factor, Erythropoietin, Vaccine, Hormone and Other
Products Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 93: Germany 15-Year Perspective for Biopharmaceuticals by
Product - Percentage Breakdown of Value Sales for Monoclonal
Antibody, Interferon, Insulin, Growth & Coagulation Factor,
Erythropoietin, Vaccine, Hormone and Other Products for the
Years 2012, 2020 & 2027

Table 94: Germany Current & Future Analysis for
Biopharmaceuticals by Application - Oncology, Blood Disorder,
Metabolic Disease, Infectious Disease, Cardiovascular Disease,
Neurological Disease, Immunology and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 95: Germany Historic Review for Biopharmaceuticals by
Application - Oncology, Blood Disorder, Metabolic Disease,
Infectious Disease, Cardiovascular Disease, Neurological
Disease, Immunology and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 96: Germany 15-Year Perspective for Biopharmaceuticals by
Application - Percentage Breakdown of Value Sales for Oncology,
Blood Disorder, Metabolic Disease, Infectious Disease,
Cardiovascular Disease, Neurological Disease, Immunology and
Other Applications for the Years 2012, 2020 & 2027

ITALY
Table 97: Italy Current & Future Analysis for
Biopharmaceuticals by Product - Monoclonal Antibody,
Interferon, Insulin, Growth & Coagulation Factor,
Erythropoietin, Vaccine, Hormone and Other Products -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 98: Italy Historic Review for Biopharmaceuticals by
Product - Monoclonal Antibody, Interferon, Insulin, Growth &
Coagulation Factor, Erythropoietin, Vaccine, Hormone and Other
Products Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 99: Italy 15-Year Perspective for Biopharmaceuticals by
Product - Percentage Breakdown of Value Sales for Monoclonal
Antibody, Interferon, Insulin, Growth & Coagulation Factor,
Erythropoietin, Vaccine, Hormone and Other Products for the
Years 2012, 2020 & 2027

Table 100: Italy Current & Future Analysis for
Biopharmaceuticals by Application - Oncology, Blood Disorder,
Metabolic Disease, Infectious Disease, Cardiovascular Disease,
Neurological Disease, Immunology and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 101: Italy Historic Review for Biopharmaceuticals by
Application - Oncology, Blood Disorder, Metabolic Disease,
Infectious Disease, Cardiovascular Disease, Neurological
Disease, Immunology and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 102: Italy 15-Year Perspective for Biopharmaceuticals by
Application - Percentage Breakdown of Value Sales for Oncology,
Blood Disorder, Metabolic Disease, Infectious Disease,
Cardiovascular Disease, Neurological Disease, Immunology and
Other Applications for the Years 2012, 2020 & 2027

UNITED KINGDOM
Biopharmaceuticals Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United Kingdom for 2023 (E)
Table 103: UK Current & Future Analysis for Biopharmaceuticals
by Product - Monoclonal Antibody, Interferon, Insulin, Growth &
Coagulation Factor, Erythropoietin, Vaccine, Hormone and Other
Products - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 104: UK Historic Review for Biopharmaceuticals by Product -
Monoclonal Antibody, Interferon, Insulin, Growth &
Coagulation Factor, Erythropoietin, Vaccine, Hormone and Other
Products Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 105: UK 15-Year Perspective for Biopharmaceuticals by
Product - Percentage Breakdown of Value Sales for Monoclonal
Antibody, Interferon, Insulin, Growth & Coagulation Factor,
Erythropoietin, Vaccine, Hormone and Other Products for the
Years 2012, 2020 & 2027

Table 106: UK Current & Future Analysis for Biopharmaceuticals
by Application - Oncology, Blood Disorder, Metabolic Disease,
Infectious Disease, Cardiovascular Disease, Neurological
Disease, Immunology and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 107: UK Historic Review for Biopharmaceuticals by
Application - Oncology, Blood Disorder, Metabolic Disease,
Infectious Disease, Cardiovascular Disease, Neurological
Disease, Immunology and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 108: UK 15-Year Perspective for Biopharmaceuticals by
Application - Percentage Breakdown of Value Sales for Oncology,
Blood Disorder, Metabolic Disease, Infectious Disease,
Cardiovascular Disease, Neurological Disease, Immunology and
Other Applications for the Years 2012, 2020 & 2027

SPAIN
Table 109: Spain Current & Future Analysis for
Biopharmaceuticals by Product - Monoclonal Antibody,
Interferon, Insulin, Growth & Coagulation Factor,
Erythropoietin, Vaccine, Hormone and Other Products -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06051422/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

              Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001